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INTRODUCTION
Breast cancer is the most common type of
cancer in American women after skin can-
cer. It is also the second deadliest cause
of fatalities in women, exceeded only by
lung cancer (1). There is a lot of varia-
tion within the tumors of an individual
and also between the tumors of different
individuals. These differences account for
assessing therapeutic resistance and pro-
gression of disease. It is a challenge to
characterize these tumors and design effec-
tive therapies to control their progression
(2). There is a dynamic interaction between
the tumors and the immune system, which
determines the fate of their existence (3).
Most tumors arise as a result of genetic
and epigenetic changes that occur within
an individual. These changes are often fol-
lowed by inflammation that helps in the
recruitment of inflammatory cells, fibrob-
lasts, and endothelial cells in the microen-
vironment of host tumor cells. The inter-
action of tumor cells and the cells of the
tumor microenvironment determines the
invasive potential of the tumors (4).
INNATE IMMUNE RESPONSES AND
CANCER
The cells of the innate immune sys-
tem, namely macrophages, dendritic cells
(DCs), natural killer (NK), NKT, and γδT-
cells, play a critical role in hot immune
responses against host tumors by vari-
ous mechanisms (5). Adaptive immune
responses play a critical role in elimina-
tion of tumor cells by generating more
specific tumor immunity and immuno-
logical memory (5). Thus, there is a con-
stant interaction between the innate and
adaptive arms of the host immune sys-
tem to generate a strong immune response
to detect and eliminate the pathogens
and mutated cells before they become
tumors (6). Pathogen-associated molecu-
lar patterns (PAMPs) are recognition mol-
ecules that are associated with groups of
pathogens. Damage-associated molecular
patterns (DAMPs) are endogenous mole-
cules created upon tissue injury. Both these
patterns signal the threat of either infection
or injury to the organism and are recog-
nized by a family of innate immune system
called the Pattern recognition receptors
(PRRs) (7–10). Toll-like receptors (TLRs)
are the most well studied among the mem-
bers of the cellular receptors and are known
to play an important role in bridging innate
and adaptive immune responses in cancer
(6). The innate immune responses gener-
ated by TLRs are known to suppress the
function of regulatory T-cells (T-regs) by
breaking tolerance and enhancing immune
responses against cancers (5, 11–13). Sig-
naling through TLR activates DCs and
macrophages to secrete IL-12, a cytokine
that directs the adaptive immune response
toward a Th1 phenotype (14). TLRs are
not only expressed on immune cells but
they are also expressed on cancer cells. The
expression of TLRs on the cell type can
have different consequences (15). Studies
suggest that TLR signaling in tumor cells
promote tumor angiogenesis and metasta-
sis. Activation or TLRs by DAMPs released
by tissue damage can attract more inflam-
matory cells to cause chronic inflammation
leading to tumor progression (16–18).
TOLL-LIKE RECEPTORS AND IMMUNE
SURVEILLANCE IN BREAST CANCER
Several TLR agonists have been demon-
strated to produce anti-tumor effects in
breast cancer (11). Some analogs of nucleic
acids that activate TLR7 and TLR9 have
been used in clinical trials to improve
anti-tumor immune response against solid
tumors. Additionally, TLR signaling has
been shown to decrease or de-repress the
effects of regulatory T-cells on DCs or
CD8+ T-cells (19, 20). Among the tumor-
infiltrating lymphocytes, a major popula-
tion (70–90%) of gammadelta (γδ) cells
called γδ1 T-cells was shown to inhibit
naive and effector T-cell responses and
block DC maturation and function (21).
γδ1 regulatory T-cells reside naturally in
the epithelial tissues and can easily migrate
to normal or malignant epithelium. These
cells can possibly expand by direct pre-
sentation of antigens by tumor cells (21).
The immunosuppressive activity of these
cells could be reversed by human TLR8
ligands both in vitro and in vivo. These
cells required MyD88, TRAF6, IKKalpha
IKKbeta, and p38alpha molecules in gam-
madelta1 cells to respond to TLR8 lig-
ands (21). In a model of human HER-
2/neu(+) breast cancer (neu-transgenic
mice), topical treatment with a TLR7 ago-
nist, imiquimod, showed significant regres-
sion of spontaneous breast cancers. Analy-
sis of gene expression data from the tumors
of these mice revealed that treatment
with imiquimod resulted in high levels in
addition to TNF-alpha and IFN-gamma.
The anti-tumor effect of imiquimod was
significantly enhanced by blocking IL-
10, thereby increasing survival in these
mice. Thus, IL-10 induction maybe a self-
regulatory mechanism used by the TLR
agonists to control excessive inflamma-
tion (22).
Other TLRs expressed on the immune
cells have also been reported to improve the
efficacy of tumor vaccines or enhancement
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of chemotherapy of breast tumors by
enhancing anti-tumor immune responses.
When polysaccharide krestin (PSK), a
TLR2 agonist was orally consumed in neu-
transgenic mice, it significantly inhibited
breast cancer growth by its action on the
CD8 (+) T-cell and NK cells but not
CD4 (+) T-cells (23). In another study,
another TLR2 agonist polysaccharide A
(PSA) was shown to cause inhibition of
immune responses by production of IL-
10 and regulatory T-cells (24). Thus, TLR2
stimulation on immune cells may also
have opposing immune effects as in the
case of PSA and PSK. Nitrogen bispho-
sphonates (NBPs) have been shown to
cause a rapid influx of neutrophils and
monocytes that was dependent via myeloid
differentiation primary response gene 88
(MyD88), a downstream adaptor mole-
cule involved in TLR and IL-1 signal-
ing. Using bone marrow chimeras, it was
demonstrated that this acute inflamma-
tory response was partially dependent on
TLR4 expressed by hematopoietic cells and
the IL-1 receptor on radioresistant cells
(25). Studies from our laboratory on car-
cinogenic polyaromatic hydrocarbon 7,12-
dimethylbenz(a)anthracene (DMBA) have
demonstrated that cell mediated immu-
nity to DMBA was dependent on TLR4
and had a protective effect against mam-
mary tumor development. This effect was
primarily mediated by IL-12 secreted by
CD11c+ cells in TLR4 proficient mice,
which lead to an IFN-γ mediated response
resulting in fewer tumors (26).
TOLL-LIKE RECEPTORS AND
IMMUNOTHERAPY OF BREAST
CANCER
Vaccination strategies using DC/breast car-
cinoma fusions were effective in generat-
ing anti-tumor immune responses patients
with metastatic breast cancer, but tumor
regression was observed in a minor group
of these patients. This was due to the
expansion of both activated and regula-
tory T-cell populations by DC/breast car-
cinoma fusions, primarily leading to sup-
pression of T-cell responses. TLR9 ago-
nist CpG oligodeoxynucleotides along with
IL-12 and IL-18 was able to reduce the
level of fusion-mediated regulatory T-cell
expansion. The regulatory T-cell response
was inhibited by using TLR agonists
that enhanced effector T-cell responses,
thus increasing the efficacy of vaccine
(27). Effective immunotherapy using com-
bination of HER-2/neu genetic vaccine
and novel agonist of TLR9 has been
reported for breast cancer. This therapy
has been reported to be associated with
antibody isotype switch and antibody-
dependent cellular cytotoxicity activity of
the of DNA-EP/Ad-based cancer vaccines
(28). Vaccination with Ad-BD2-E1A (E1B-
deleted oncolytic adenovirus expressing
beta-defensin-2) vaccine inhibited primary
breast tumor growth and blocked metas-
tasis in a TLR4 dependent manner, thus
suggesting the critical role of TLR4 in
the induction of anti-tumor immunity by
Ad-BD2-E1A (29).
TOLL-LIKE RECEPTORS AND
CHEMOTHERAPY OF BREAST CANCER
The efficacy of chemotherapy is defined
by their ability to perturb the divi-
sion of tumor cells. A successful out-
come of chemotherapy or radiotherapy
also involves inclusion of an adjuvant that
would enhance the efficacy of chemo-
or radiotherapy. One such adjuvant, high
mobility group box 1 protein (HMGB1)
has been successfully used in therapy of
breast cancer. Dying tumor cells release
HMGB1 that has been shown to activate
TLR4 on DCs. It was shown that TLR4
expressed on DCs was required for the
cross presentation of tumor antigens and
the promotion of tumor specific cytotoxic
T-cell responses. Breast cancer patients
harboring the loss-of-function Asp299Gly
polymorphism of TLR4 relapsed ear-
lier after receiving anthracycline-based
chemotherapy. These data suggests that
HMGB1- and TLR4-dependent immune
responses elicited by conventional can-
cer treatment may increase the probabil-
ity of achieving a lasting therapeutic suc-
cess (30). When small nucleotide poly-
morphisms (SNPs) in TLR2, TLR3, TLR4,
and TLR9 were assessed for their associ-
ation with breast cancer, no association
was found. However, population genet-
ics data has revealed that a hypomorphic
variant of TLR4 (p.Asp299Gly) allele was
found with no specific allelic frequency
(8.4%) in the Croatian population com-
pared to other Caucasians (6.5–10%) (31).
The development of drugs targeting TLRs
is an emerging area, and there are about 20
drugs that are in pre-clinical and clinical
trials (32).
TOLL-LIKE RECEPTORS AND BREAST
CANCER CELLS
In addition to their expression on immune
cells, TLRs are also expressed on tumor
cells (15). Activation of TLR expressed
on tumor cells may enhance tumor
growth by increasing pro-survival signals,
anti-apoptotic signals, tumor promoting
cytokines, angiogenesis, and invasiveness
(33, 34). Among the TLRs (TLR1-10),
expressed on human breast cancer cell
line MDA-MB-231, expression of TLR4
was found to be the highest, and knock-
down of TLR4 gene resulted in signif-
icant cell death and inhibition of IL-6
and IL-8 cytokines, compared with vec-
tor control (33). In another study, TLR9
was shown to increase invasion of MDA-
MB-231 cells, by increasing the activity
of matrix metalloproteinase 13 (MMP13)
(35). TLR3, TLR4, and TLR9 have been
shown to be highly expressed in human
breast tumors. There was also an increase
in the expression of TLR4 by mononuclear
inflammatory cells and TLR9 by fibroblast-
like cells in mammary tumors. There was
more metastasis in TLR3 expressing tumor
cells, TLR4 expressing inflammatory cells
but not in TLR9 expressing fibroblasts
like cells (36). TLR9 isoforms A and B
has been detected in clinical breast cancer,
and ERα and sex steroid hormones have
been shown to contribute to its invasive-
ness. TLR9 expression was also found to
be affected by the hormonal cancer ther-
apy using bicalutamide (37). In a ran-
domized clinical trial using poly (A:U)
dsRNA, TLR3 agonist, chemotherapy was
enhanced in patients with TLR3-positive
cancers. Chemotherapy using poly A:U
was successful only when it was combined
with an immunochemotherapeutic regi-
men of vaccination against tumor anti-
gens (38). In a recent study, it was found
that activation of TLR5 on breast cancer
cells by its agonist flagellin, led to inhi-
bition of cell proliferation and anchor-
age dependent cell growth. This was fur-
ther confirmed in mouse xenograft mod-
els using human breast cancer cells. This
inhibitory activity was further confirmed
in vivo using mouse xenografts of human
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FIGURE 1 | Diagram to depict the effect of activation of toll-like receptors (TLRs) on breast cancer
cells versus immune cells. Activation of TLRs on breast cancer cells results in chronic inflammation and
recruitment of macrophages (MΦ) and regulatory T-cells (T-reg) in the tumor microenvironment that cause
suppression of immune responses and progression of tumor growth. Activation of TLRs by TLR agonists
cause infiltration of dendritic cells (DC), natural killer (NK) cells, and cytotoxic T-cells (CTL) that result in
suppression of tumor growth.
breast cancer cells (39). Inflammatory sig-
nals generated by TLR signaling have also
been reported to increase expression of
chemokines, thus causing an influx of Th17
cells by tumor cells and tumor derived
fibroblasts (40).
CONCLUSIONS AND PERSPECTIVES
Discovery of the role of TLRs in can-
cer biology have paved the way for devel-
opment of new therapies targeting TLRs.
There is a lot of interest to study the rela-
tion between inflammation and cancer as
it has been termed as the seventh hall-
mark of cancer. TLRs play an important
role in inflammation mediated cancers as
well as cancer related inflammation. Acti-
vation of TLRs for therapy may be an
exciting proposition, but one has to be
careful as over activation of TLRs can also
lead to development of tumors (Figure 1).
Thus, regulatory mechanisms should also
be taken into account before using TLRs for
cancer therapy. Furthermore, molecular
and genetic analysis of breast cancer sub-
types should be considered before deciding
the course of therapy with TLRs. There
are some reports on the role of genetic
polymorphisms in TLRs in the outcome of
breast cancer therapy. More studies need
to be conducted to determine whether the
loss or gain of function polymorphisms in
TLRs is an indicator of disease outcome or
therapy.
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